Gaya Herald

Head and Neck Cancer Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – L-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp

 Breaking News
  • No posts were found

Head and Neck Cancer Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – L-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp

November 15
00:11 2022
The head and neck cancer market is expected to show positive growth, mainly attributed to the increasing incident cases and the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more drug development.

DelveInsight’s Head and Neck Cancer Market Insights report includes a comprehensive understanding of current treatment practices, head and neck cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

 

Key Takeaways from the Head and Neck Cancer Market Report

  • As per DelveInsight analysis, the head and neck cancer market size in the 7MM was approximately USD 2.9 billion in 2021.
  • As per the estimates, the total head and neck cancer incident cases in the 7MM were approximately 158K in 2021. 
  • Leading head and neck cancer companies such as CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others are developing novel head and neck cancer drugs that can be available in the head and neck cancer market in the upcoming years.
  • The head and neck cancer therapies in the pipeline include Leukocyte Interleukin (MULTIKINE), Toripalimab, Cabozantinib, Eftilagimod alpha (Efti/IMP321), LN-145 (Tumor Infiltrating Lymphocytes), Tislelizumab, Penpulimab/AK105, Tipifarnib, XEVINAPANT (Debio 1143), TECENTRIQ (atezolizumab), Cyramza (ramucirumab), and others.
  • The head and neck cancer market is expected to grow due to factors such as an increase in the patient pool and the expected entry of emerging therapies.

 

Discover which therapies are expected to grab the major head and neck cancer market share @ Head and Neck Cancer Market Report

 

Head and Neck Cancer Overview

Head and neck cancer (HNC) usually begins in the squamous cells – also known as squamous cell carcinomas of the head and neck – that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box), but it can also begin in the salivary glands, sinuses, muscles, or nerves. Alcohol and tobacco use are the two most important risk factors for head and neck causes. 

Head and neck cancer symptoms include a lump in the neck or a sore in the mouth or throat that does not heal, a persistent sore throat, difficulty swallowing, and a change or hoarseness in the voice; however, these head and neck cancer symptoms can also be caused by other, less serious illnesses.

Physical examination/blood and urine tests, endoscopy, biopsy, biomarker testing of the tumor, X-ray/barium swallow, panoramic radiograph, ultrasound, magnetic resonance imaging, bone scan, and other tests are used for head and neck diagnosis.

 

Head and Neck Cancer Epidemiology Segmentation

  • DelveInsight estimates that there were approximately 158K incident cases of head and neck cancer in the 7MM in 2021.
  • Among the EU5 countries, Germany had the highest number of head and neck cancer incident cases in 2021.

 

The head and neck cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Incident Cases of Head and Neck Cancer
  • HPV-specific Incident Cases of Head and Neck Cancer
  • Site-specific Incident Cases of Head and Neck Cancer
  • Molecular Alteration-specific Incident Cases of Head and Neck Cancer
  • Stage-specific Incident Cases of Head and Neck Cancer

 

Download the report to understand which factors are driving head and neck cancer epidemiology trends @ Head and Neck Cancer Epidemiological Insights

 

Head and Neck Cancer Treatment Market 

Chemotherapy has widely used in all lines of head and neck treatment among all available therapeutic options. Numerous drugs have been identified with the advancement of medical technologies and increased research and development activities. Immunotherapeutic options for treating HNC patients have also been identified.

Overall, head and neck cancer treatment options for patients with HNC include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Pharmacological therapies are primarily used to destroy cancer cells and are administered systematically or locally (by a medical oncologist). Chemotherapy, targeted therapy, and immunotherapy are some of the pharmacological head and neck cancer treatments available to HNC patients.

Across all countries, the most common first-line systemic therapy regimens were platinum-based combinations, such as platinum + 5-F, cetuximab + platinum 5-FU, or taxane + platinum 5-FU. However, the use of different platinum-based combinations varied significantly across countries; administration of cetuximab + platinum 5-FU was common in Italy, Germany, and Spain. In the United Kingdom, platinum with 5-FU was the most commonly used first-line regimen.

 

Head and Neck Cancer Pipeline Therapies and Key Companies

  • Leukocyte Interleukin (MULTIKINE): CEL-SCI
  • Toripalimab: Junshi Biosciences/Coherus
  • Cabozantinib: Exelixis
  • Eftilagimod alpha (Efti/IMP321): Immutep S.A.S./Merck Sharp & Dohme LLC
  • LN-145 (Tumor Infiltrating Lymphocytes): Iovance Biotherapeutics
  • Tislelizumab: BeiGene
  • Penpulimab/AK105: Akeso/Chia Tai-Tianqing
  • Tipifarnib: Kura Oncology
  • XEVINAPANT (Debio 1143): Merck KGaA
  • TECENTRIQ (atezolizumab): Hoffmann-La Roche
  • Cyramza (ramucirumab): Eli Lilly and Company

 

Report Metrics 

Details

Study Period

2019–2032

Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Base Year 

2021

Market CAGR

5.1 %

Market Size in 2021

USD 2.9 Billion

Key Head and Neck Cancer Companies

CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others

Key Head and Neck Cancer Therapies

Leukocyte Interleukin (MULTIKINE), Toripalimab, Cabozantinib, Eftilagimod alpha (Efti/IMP321), LN-145 (Tumor Infiltrating Lymphocytes), Tislelizumab, Penpulimab/AK105, Tipifarnib, XEVINAPANT (Debio 1143), TECENTRIQ (atezolizumab), Cyramza (ramucirumab), and others

 

Scope of the Head and Neck Cancer Market Report

  • Head and Neck Cancer Therapeutic Assessment: Head and Neck Cancer current marketed and emerging therapies
  • Head and Neck Cancer Market Dynamics: Head and Neck Cancer market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Head and Neck Cancer Unmet Needs, KOL’s views, Analyst’s views, Head and Neck Cancer Market Access and Reimbursement

 

Discover more about drugs for head and neck cancer in development @ Head and Neck Cancer Clinical Trials

 

Table of Contents

1.

Head and Neck Cancer Market Key Insights

2.

Head and Neck Cancer Market Report Introduction

3.

Head and Neck Cancer Market Overview at a Glance

4.

Head and Neck Cancer Market Executive Summary

5.

Disease Background and Overview

6.

Head and Neck Cancer Treatment and Management

7.

Head and Neck Cancer Epidemiology and Patient Population

8.

Patient Journey

9.

Head and Neck Cancer Emerging Drugs

10.

Seven Major Head and Neck Cancer Market Analysis

11.

Head and Neck Cancer Market Outlook

12.

Potential of Current and Emerging Therapies

13.

KOL Views

14.

Head and Neck Cancer Market Drivers

15.

Head and Neck Cancer Market Barriers

16.

Unmet Needs

17.

SWOT Analysis

18.

Appendix

19.

DelveInsight Capabilities

20.

Disclaimer

21.

About DelveInsight

 

To know more about head and neck cancer treatment options, visit @ New Treatment for Head and Neck Cancer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/